Coronavirus Notebook: EU Invests In Convalescent Plasma, ACT-Accelerator Wants More Vaccines
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
You may also be interested in...
Coronavirus Notebook: EMA Expects First Vaccine Efficacy Data Soon, ACT-Accelerator Needs Urgent Funding
Talks are continuing on COVID-19 vaccine supply in the EU, with Pfizer/BioNTech’s BNT-162 the latest in the frame for the delivery of 200 million doses. The European Commission has also said that if the vaccines fail to perform, any money paid in advance purchase deals should go towards further research.
The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19.
Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP
AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.